Department of Human and Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
Institute of Molecular Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
Hepatology. 2023 Jul 1;78(1):45-57. doi: 10.1097/HEP.0000000000000044. Epub 2023 Jan 13.
Drug-induced liver injury occurs frequently and can be life threatening. Although drug-induced liver injury is mainly caused by the direct drug cytotoxicity, increasing evidence suggests that the interplay between hepatocytes and immune cells can define this pathogenic process. Here, we interrogate the role of the pattern recognition scavenger receptor A (SRA) for regulating hepatic inflammation and drug-induced liver injury.
Using acetaminophen (APAP) or halothane-induced liver injury models, we showed that SRA loss renders mice highly susceptible to drug hepatotoxicity, indicated by the increased mortality and liver pathology. Mechanistic studies revealed that APAP-induced liver injury exaggerated in the absence of SRA was associated with the decreased anti-inflammatory and prosurvival cytokine IL-10 concomitant with excessive hepatic inflammation. The similar correlation between SRA and IL-10 expression was also seen in human following APAP uptake. Bone marrow reconstitution and liposomal clodronate depletion studies established that the hepatoprotective activity of SRA mostly resized in the immune sentinel KCs. Furthermore, SRA-facilitated IL-10 production by KCs in response to injured hepatocytes mitigated activation of the Jun N-terminal kinase-mediated signaling pathway in hepatocytes. In addition, supplemental use of IL-10 with N -acetylcysteine, only approved treatment of APAP overdose, conferred mice improved protection from APAP-induced liver injury.
We identify a novel hepatocyte-extrinsic pathway governed by the immune receptor SRA that maintains liver homeostasis upon drug insult. Giving that drug (ie, APAP) overdose is the leading cause of acute liver failure, targeting this hepatoprotective SRA-IL-10 axis may provide new opportunities to optimize the current management of drug-induced liver injury.
药物性肝损伤较为常见,甚至可能危及生命。尽管药物性肝损伤主要是由药物直接细胞毒性引起的,但越来越多的证据表明,肝细胞与免疫细胞之间的相互作用可以决定这一致病过程。在这里,我们探讨了模式识别清道夫受体 A(SRA)在调节肝炎症和药物性肝损伤中的作用。
我们使用对乙酰氨基酚(APAP)或卤烷诱导的肝损伤模型,表明 SRA 缺失使小鼠对药物肝毒性高度敏感,表现在死亡率和肝病理增加。机制研究表明,SRA 缺失时 APAP 诱导的肝损伤加剧与抗炎和促生存细胞因子 IL-10 减少以及过度肝炎症有关。在人类服用 APAP 后,也观察到 SRA 与 IL-10 表达之间的类似相关性。骨髓重建和脂质体氯膦酸盐耗竭研究表明,SRA 的肝保护活性主要由免疫哨兵库普弗细胞(KC)介导。此外,SRA 促进 KC 对受损肝细胞产生的 IL-10 减轻了肝细胞中 Jun N-末端激酶介导的信号通路的激活。此外,补充使用白细胞介素 10(IL-10)与 N-乙酰半胱氨酸(仅批准用于治疗 APAP 过量)联合使用,可使小鼠对 APAP 诱导的肝损伤的保护作用得到改善。
我们发现了一种新的肝细胞外途径,该途径由免疫受体 SRA 调控,在药物损伤时维持肝脏内稳态。鉴于药物(即 APAP)过量是急性肝衰竭的主要原因,靶向该肝保护 SRA-IL-10 轴可能为优化当前药物性肝损伤的管理提供新的机会。